Unknown

Dataset Information

0

Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy.


ABSTRACT: INTRODUCTION:In patients with nonvalvular atrial fibrillation (NVAF) receiving oral anticoagulants (OACs), reversal of coagulopathy can be achieved with specific reversal drugs such as idarucizumab, which is indicated for use in patients treated with dabigatran for cases of life-threatening or uncontrolled bleeding or during emergency procedures that may cause serious bleeding. This study examined the incidence rate (IR) of emergency surgeries and major bleeding episodes associated with fractures and trauma in Japanese patients with NVAF receiving OACs. METHODS:This retrospective, non-interventional analysis of health insurance claims was conducted using data from 62,888 OAC-naive adult patients with NVAF who initiated dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban between March 2011 and June 2016. The primary endpoint was overall IR of emergency surgery or major bleeding due to fracture or trauma. RESULTS:Overall IR of emergency surgery or major bleeding due to fracture or trauma considering outcomes until OAC discontinuation was 0.489 per 100 patient-years (PY) (95% confidence interval [CI] 0.406-0.572). Considering first OAC exposure only, the IR was 0.483 per 100 PY (95% CI 0.394-0.573). Emergency surgery/major bleeding events due to fracture or trauma was highest in those aged???75 years (0.611 per 100 PY [95% CI 0.481-0.741]). CONCLUSIONS:Fewer than one in 200 patients per year with NVAF receiving OACs experience emergency surgeries and major bleeding episodes associated with fractures and trauma; however, the IR of these events is markedly higher in patients of advanced age. TRIAL REGISTRATION:ClinicalTrials.gov 207, NCT03254147.

SUBMITTER: Yasaka M 

PROVIDER: S-EPMC7237605 | BioStudies | 2020-01-01

SECONDARY ACCESSION(S): NCT03254147

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5634552 | BioStudies
2016-01-01 | S-EPMC5051466 | BioStudies
2018-01-01 | S-EPMC6714709 | BioStudies
1000-01-01 | S-EPMC6042605 | BioStudies
2019-01-01 | S-EPMC6549060 | BioStudies
2019-01-01 | S-EPMC6449182 | BioStudies
2020-01-01 | S-EPMC7581660 | BioStudies
1000-01-01 | S-EPMC5388034 | BioStudies
2019-01-01 | S-EPMC6855694 | BioStudies
2019-01-01 | S-EPMC6433218 | BioStudies